Document Detail


Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases.
MedLine Citation:
PMID:  20470005     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Solid tumors of various etiologies can be treated efficiently by electrochemotherapy (ECT), a combined use of electroporation (EP) and chemotherapeutic drugs, such as bleomycin and cisplatin. EP alone and ECT in particular, induce a profound reduction in tumor blood flow, which contributes to the antitumor effect. After EP and ECT, the time course of blood flow changes and follows the same two-phase pattern. The first rapid and short-lived vasoconstriction phase is followed by the second much longer-lived phase resulting from disrupted cytoskeletal structures and a compromised barrier function of the microvascular endothelium. In the case of ECT, however, tumor vascular endothelial cells are also affected by the chemotherapeutic drug, which leads to irrecoverable damage to tumor vessels and to a further decrease in tumor blood flow within hours after application of ECT. Tumor cells surviving the direct effects of ECT are consequently exposed to lack of oxygen and nutrients and are pushed into the secondary cascade of induced cell death. Clinically, the antitumor effectiveness of ECT has been proven extensively in the treatment of melanoma metastases, with 70-80% complete responses. The antivascular effects of ECT were also exploited for palliative treatment of bleeding melanoma metastases, with immediate cessation of bleeding and very good antitumor effectiveness. The antivascular effect of ECT is of utmost importance for translation of ECT into the treatment of deep-seated tumors, especially in well vascularized organs, such as the liver, where it prevents bleeding of the treated area.
Authors:
Tomaz Jarm; Maja Cemazar; Damijan Miklavcic; Gregor Sersa
Related Documents :
17215365 - Biomimetic amplification of nanoparticle homing to tumors.
16736105 - Molecular addresses of tumors: selection by in vivo phage display.
424175 - Diagnosis and management of anterior uveal tumors.
21251905 - Consistent interactions between tumor cell il-6 and macrophage tnf-α enhance the growt...
11896785 - Ultrapulse co2 used for the successful treatment of basal cell carcinomas found in pati...
21490835 - Esophageal granular cell tumor and eosinophilic esophagitis: two interesting entities i...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of anticancer therapy     Volume:  10     ISSN:  1744-8328     ISO Abbreviation:  Expert Rev Anticancer Ther     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-05-17     Completed Date:  2011-01-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101123358     Medline TA:  Expert Rev Anticancer Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  729-46     Citation Subset:  IM    
Affiliation:
University of Ljubljana, Faculty of Electrical Engineering, Trzaska 25, SI-1000 Ljubljana, Slovenia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antineoplastic Agents / therapeutic use
Blood Flow Velocity / physiology
Electrochemotherapy / methods*
Hemorrhage / drug therapy,  prevention & control*
Humans
Liver Neoplasms / blood supply,  drug therapy,  secondary
Melanoma / blood supply,  drug therapy,  secondary
Neoplasms / blood supply*,  drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma.
Next Document:  Erectile dysfunction after robot-assisted radical prostatectomy.